aTyr Pharma to Present at the Jefferies London Healthcare Conference
aTyr Pharma, a biotherapeutics company, announced that Dr. Sanjay S. Shukla will present a corporate overview at the Jefferies London Healthcare Conference on November 15, 2022. The presentation is scheduled for 3:15 PM GMT / 10:15 AM EST in London, U.K. Following the presentation, a replay will be available on the company’s website for at least 90 days. aTyr specializes in developing first-in-class medicines via its proprietary tRNA synthetase platform, with a focus on efzofitimod, a candidate targeting fibrotic lung disease.
- None.
- None.
SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the Jefferies London Healthcare Conference, which is scheduled to take place November 15 – 17, 2022, in London, U.K.
Details of the presentation appear below:
Conference: Jefferies London Healthcare Conference
Date: Tuesday, November 15, 2022
Time: 3:15pm GMT / 10:15am EST
Location: London, U.K.
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. An audio webcast of the event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.
| IMMEDIATE RELEASE |
| Contact: |
| Ashlee Dunston |
| Director, Investor Relations and Corporate Communications |
| adunston@atyrpharma.com |
FAQ
When is aTyr Pharma's presentation at the Jefferies London Healthcare Conference?
Who will present at the Jefferies London Healthcare Conference for aTyr Pharma?
What is efzofitimod, the focus of aTyr Pharma's research?
How can I access the audio webcast of aTyr Pharma's presentation?
What is the significance of the tRNA synthetase platform for aTyr Pharma?
